[PubMed] [Google Scholar] Cerovecki T., Bojanic I., Brcic L., Radic B., Vukoja I., Seiwerth S., et al
The SURPASS program (for type 2 diabetes) and SURMOUNT program (for obesity) together enrolled over 20,000 participants across multiple Phase III trials
Wolters Kluwer Health Kluwer
Long-term estrogen therapy without a progestogen in women with a uterus is associated with an elevated risk of endometrial neoplasia
The main difference in GHK-Cu vs BPC-157 is that GHK-Cu is more often associated with collagen and skin regeneration pathways, while BPC-157 is more often associated with tendon, ligament, muscle, gut, and systemic recovery pathways
The refusal to provide this essential treatment a day early, when the patient is symptomatic, is fundamentally different from a dietary suggestion